Merck (MRK) vs Vertex Pharmaceuticals (VRTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Merck (MRK) has outperformed Vertex Pharmaceuticals (VRTX) over the past year, gaining 36.8% versus a gain of 20.7%. Over five years, VRTX leads with a +180.5% price change compared with +68.9% for MRK. Merck is the larger company by market cap ($329.65 billion vs $130.58 billion), about 2.5 times the size, while Vertex Pharmaceuticals is growing revenue faster (+8.9% vs +1.3%).
On valuation, Merck trades at a lower forward P/E (14.9x vs 25.9x for Vertex Pharmaceuticals). Merck pays a dividend yielding 2.51%, while Vertex Pharmaceuticals does not currently pay one. Vertex Pharmaceuticals converts more of its revenue into profit, with a net margin of 32.9% versus 28.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MRK | VRTX |
|---|---|---|
| Share price | $133.72 | $515.02 |
| Market cap | $329.65B | $130.58B |
| 1-day change | +0.69% | -1.08% |
| YTD return | +27.04% | +13.60% |
| 1-year return | +36.78% | +20.68% |
| 5-year return | +68.92% | +180.53% |
| P/E ratio (TTM) | 135.07 | 33.14 |
| Forward P/E | 14.92 | 25.86 |
| EPS (TTM) | $0.99 | $15.54 |
| Dividend yield | 2.51% | 0.00% |
| Annual dividend | $3.36 | $0.00 |
| Revenue (latest FY) | $65.01B | $12.00B |
| Revenue growth (YoY) | +1.31% | +8.90% |
| Net income (latest FY) | $18.25B | $3.95B |
| Gross margin | 74.80% | 86.24% |
| Operating margin | — | 34.77% |
| Net margin | 28.08% | 32.94% |
| 52-week high | $156.92 | $568.67 |
| 52-week low | $96.06 | $412.27 |
| Distance from 52-week high | -14.78% | -9.43% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +20.80% | +15.60% |
| Average volume | 9.81M | 1.25M |
| Shares outstanding | 2.47B | 253.54M |
| Employees | 73,000 | 6,400 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Merck is about 2.5 times larger than Vertex Pharmaceuticals by market value ($329.65B vs $130.58B).
- MRK has outperformed VRTX by 16.1 percentage points over the past year.
- Merck trades at a higher earnings multiple (135.1x vs 33.1x trailing P/E).
- Merck offers a meaningfully higher dividend yield (2.51% vs 0.00%).
- Vertex Pharmaceuticals grew revenue faster in its latest fiscal year (+8.90% vs +1.31%).
About Merck
MRK stock →Merck & Co., Inc. operates as a healthcare company worldwide.
Health Care · Biotechnology: Pharmaceutical Preparations · 73,000 employees
About Vertex Pharmaceuticals
VRTX stock →Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 6,400 employees
MRK vs VRTX FAQ
Which is bigger, Merck or Vertex Pharmaceuticals?
Merck (MRK) is larger, with a market capitalization of $329.65B compared with $130.58B for Vertex Pharmaceuticals (VRTX).
Which stock has performed better over the past year, MRK or VRTX?
MRK returned +36.78% over the past 12 months, compared with +20.68% for VRTX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, MRK or VRTX?
VRTX has the lower trailing P/E at 33.1, versus 135.1 for MRK. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Merck or Vertex Pharmaceuticals?
Merck pays a dividend yielding 2.51%, while Vertex Pharmaceuticals does not currently pay a regular dividend.
Are Merck and Vertex Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.